Eckel Florian, Schneider Günter, Schmid Roland M
Technical University of Munich, Department of Internal Medicine, Germany.
Expert Opin Investig Drugs. 2006 Nov;15(11):1395-410. doi: 10.1517/13543784.15.11.1395.
Pancreatic cancer is one of the most common causes of cancer-related death. Despite the advances of the molecular pathogenesis, pancreatic cancer remains a major unsolved health problem. Overall, the 5-year survival rate is < 5% and only approximately 20% of the 10% of patients with resectable disease survive 5 years. Recently, the European Study Group for Pancreatic Cancer 1 trial demonstrated substantially increased survival from adjuvant chemotherapy with 5-fluorouracil-folinic acid and preliminary data showed prolonged disease-free survival from adjuvant gemcitabine. Current palliative therapeutic approaches mostly focused on evaluating chemotherapy regimens in which gemcitabine is combined with a second cytotoxic agent. Recently, large randomised trials of combinations of gemcitabine with either capecitabine or with erlotinib demonstrated prolonged survival and 1-year survival rates of approximately 25%. The advance of molecular biology has led to the elucidation of molecular events that are important for pancreatic carcinogenesis and has provided a foundation for the development of novel chemotherapeutic and biological agents that appear to be promising and are likely to play a future role in the treatment of patients with advanced pancreatic cancer.
胰腺癌是癌症相关死亡的最常见原因之一。尽管分子发病机制取得了进展，但胰腺癌仍然是一个主要的未解决的健康问题。总体而言，5年生存率<5%，在可切除疾病患者中，只有约10%的患者中有20%能存活5年。最近，欧洲胰腺癌研究组1试验表明，5-氟尿嘧啶-亚叶酸辅助化疗可显著提高生存率，初步数据显示吉西他滨辅助化疗可延长无病生存期。目前的姑息治疗方法主要集中在评估吉西他滨与第二种细胞毒性药物联合使用的化疗方案。最近，吉西他滨与卡培他滨或厄洛替尼联合使用的大型随机试验表明，生存期延长，1年生存率约为25%。分子生物学的进展已导致对胰腺癌发生过程中重要分子事件的阐明，并为开发新型化疗和生物制剂奠定了基础，这些制剂似乎很有前景，可能在晚期胰腺癌患者的治疗中发挥未来作用。
